Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S NVO and Eli Lilly And Co LLY achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1 market could surpass$150 billion by 2030. Once Botox symbolized aspirational self-care; now semaglutide injections are the ultimate status flex — one that's also fueling a pharma gold rush.Track NVO stock here.Celebrities Fuel The ...